Anthracyclines have been the backbone of acute leukemia therapy in the adult for many years, but little attention has been paid to the long-term toxicity of these agents in this disease because of the poor survival of this population of patients. Recent studies have examined dose-intensified daunorubicin with dosages as high as 95 mg/m 2 daily ؋ 3 in this population with the attendant concerns of both acute and chronic toxicity. We have examined three human leukemia cell lines in vitro, treated with either daunorubicin, mitoxantrone, with or without cytosine arabinoside in the presence of dexrazoxane to determine whether such treatment would be synergistic or antagonistic. AML-193, CRF-SB, and Molt-4 cell lines were grown to confluence, plated into microtiter dishes and incubated for 72 h with varying concentrations of the above drugs. Cytotoxicity was determined by the MTT assay, and synergy or antagonism by median effect analysis. Dexrazoxane demonstrated additive or synergistic cytotoxic effects (CI Ͻ1) under most conditions. The triplet of daunorubicin, cytosine arabinoside, and dexrazoxane showed profound synergy in all three cell lines. These effects occurred at clinically achievable levels. If high dosages of anthracyclines are contemplated in this population, these preclinical data suggest that the addition of dexrazoxane to classical therapy is not antagonistic and thus may allow an investigation of the role of dexrazoxane as a cardiac protectant. Leukemia (2001) 15, 1517-1520.
Introduction
The treatment of acute leukemia in the adult has evolved into the use of dose-intense anthracyclines in induction therapy. 1, 2 Recent CALGB leukemia studies have used induction dosages of daunorubicin as high as 95 mg/m 2 daily × 3. 3 Although the long-term consequences of anthracycline therapy have been well recognized in children, 4 ,5 the potential risk of such therapy in the adult only becomes meaningful as survival is improved.
1 Dexrazoxane (ICRF-187, AD 529) is the (+) enantiomer of ICRF-159 with greater solubility than the racemic mixture found in ICRF-159. 6 For two decades, preclinical data had suggested that dexrazoxane would reduce daunorubicin toxicity 7, 8 and there is ample data in solid tumor patients receiving this agent with anthracyclines that chronic toxicity is reduced. [8] [9] [10] [11] However, use of this agent has been tempered by the finding that dexrazoxane as a single therapeutic agent was disappointing in phase II leukemia trials. [12] [13] [14] The use of this agent in treatment of human adult leukemia in combination with anthracyclines is also very limited with no large trials to determine whether or not the drug would inhibit efficacy of the antitumor treatment. No adverse findings were seen in the nine patients reported. 15, 16 Preclinical studies of dexrazoxane in cell lines have led to 17 In L1210 murine leukemia, enhanced survival was seen in animals receiving the combination of daunorubicin with dexrazoxane rather than daunorubicin alone. 18 This drug also reduced acute daunorubicin toxicity in mice 8 and in Syrian golden hamsters 19 suggesting that the chemoprotective effects were not just limited to doxorubicin. Dexrazoxane has also been demonstrated to impair the emergence of drug resistance. When the human leukemia cell line K562 is incubated with both doxorubicin and dexrazoxane compared to doxorubicin alone, the expression of P-glycoprotein (MDR-1) drug resistance is suppressed. 20 This mechanism of suppression of multidrug resistance occurred at nontoxic concentrations of dexrazoxane and did not involve binding to P-glycoprotein. 20 However, recent studies into the mechanism of action of dexrazoxane have also suggested that the drug may antagonize the topoisomerase II actions of anthracyclines 21 and reduce the cytotoxicity of anthracyclines in vitro. 22 We therefore have restudied this agent in vitro in combination with agents used in acute leukemia using median effect analysis to determine synergy or antagonism, 23 as the drug would be attractive if it offers some degree of cardioprotection without adversely affecting the antileukemic effect.
Materials and methods
Daunorubicin, mitoxantrone (an anthracinedione), and cytosine arabinoside were obtained from Sigma-Aldrich (St Louis, MO, USA). Dexrazoxane was obtained from clinical stock. The methodology used for cell culture and median effect analysis has been previously described. [24] [25] [26] Three leukemia cell lines: AML-193, CCRF-SB, and MOLT-4 (all parental lines) were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA), grown to confluence in T 150 tissue culture flasks (Corning Glass Works, Corning, NY, USA) using RPMI 1640 (Gibco, Grand Island, NY, USA) with 5% CO 2 and 10% heat inactivated fetal calf serum. All cultures contained penicillin (100 g/ml), streptomycin (0.25 g/ml), and glutamine to a final concentration of 2 mM.
All cell lines were repeatedly tested for mycoplasma and had viabilities by Trypan blue exclusion greater than 95%. Harvested cells were aliquoted into 96-well dishes (Falcon 3072) at concentrations of 5000-8000 cells per well. The cells were then cultured for 24 h, cytotoxic agents or solvent controls were introduced for a 72 h incubation, and cell growth evaluated by a MTT (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide) assay using a BioRad 3550 microplate reader (BioRad, Hercules, CA, USA). 26 IC 50 (the dose of drug needed to cause cytotoxicity in 50% of the cells) concentrations were determined by the EZ-ED50 Program (Perrella Scientific, Conyers, CA, USA). All reported values are the means of at least three experiments with each study having four wells per dose level. In addition, the cytotoxicity of selec-ted combinations was measured serially over 72 h using the MTT assay at concentrations which are known to be achieved clinically.
Median effect analysis, a measure of synergism or antagonism based upon the Hill equation, was determined by the method of Chou and Talalay, 23 using their computer program 27 to determine the CI (combination index) which reflects synergy when less than 1, additive effects when equal to 1, and antagonism when greater than 1. The advantage of this method is that up to three agents can be evaluated for synergistic effects at the same time. Fixed drug ratios above and below the IC 50 (the concentration of drug required to exert a 50% cytotoxic effect) with a range of 0.03125 N to 8 N where N is a value near the IC 50 of an individual drug were explored by incubating the drug combinations with cells for 72 h and then determining the degree of cytotoxicity by the MTT assay. Fa is defined as the fraction of cells affected, and a plot of log dose vs log (Fa/1 − Fa) gives parallel slopes if no biologic interaction is present (mutually exclusive) or converge if there is an interaction between the drugs (mutually nonexclusive) thus suggesting the appropriate model to determine the CI.
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Results
The drug concentrations required for 50% cytotoxic effect for dexrazoxane, daunorubicin, and cytosine arabinoside are shown in Table 1 . Dexrazoxane demonstrated little cytotoxic activity in these cell lines needing near millimole concentrations to achieve an IC 50 , thus reflecting the clinical experience of this agent. In contrast, both daunorubicin and cytosine arabinoside were active in micromolar concentrations. A 3-day incubation of drug with cells was selected as most anthracycline regimens in acute leukemia use a 3-day schedule of treatment.
Plots of log dose vs log (Fa/1 − Fa) revealed that the drugs were mutually nonexclusive suggesting that there was a biological interaction between agents. The CI was therefore chosen with this criterion. This criterion is also more conservative in assigning an effect to be synergistic. 23 The CI was calculated at the Fa 50 (the point where a 50% effect on the cells occurs) as the model offers a linear approximation for a nonlinear equation and thus is inaccurate at extreme values of Fa. 28, 29 The results of 72-h incubations of cytotoxic drugs with dexrazoxane are shown in Table 2 . Although dexrazoxane demonstrates synergistic effects with cytosine arabinoside, daunorubicin, mitoxantrone, and doublet combinations of cytotoxic agents under most conditions, some of these effects are cell line-specific in that antagonism between dexrazoxane and mitoxantrone was noted in the CCRF-SB cell line (CI = 1.55). Of interest, dexrazoxane was synergistic in all cell lines when combined with the doublet of daunorubicin and cytosine arabinoside (Table 2) . To demonstrate that the synergistic response determined by median effect analysis reflects clinical drug concentrations, the cell lines were incubated over a 72-h period with concentrations of dexrazoxane which were attained in the plasma of patients in the phase I trials. 30 Cytotoxicity was measured by the MTT assay every 24 h, demonstrating a dose-related increase in cytotoxic effect when the dexrazoxane concentration is increased as shown for the AML-193 cell line ( Figure  1 ) with similar results for the other two cell lines. There was no evidence for antagonism over the 72-h observational period.
Discussion
Although dexrazoxane has been in clinical trials for over two decades, the use of this agent in acute leukemia in the adult has been limited by dexrazoxane's poor single agent activity and by fears that it might attenuate the cytotoxic effects of anthracycline treatment. In Chinese hamster ovary cells, incubation of cells with dexrazoxane prior to administration of daunorubicin resulted in antagonism of cytotoxic effects. In contrast, concurrent exposure of both drugs did not. 31 In our own experiments, concurrent exposure of dexrazoxane with mitoxantrone in CCRF-SB cells led to antagonism, thus suggesting that some of these effects could be cell line-specific. In contrast, the use of dexrazoxane with daunorubicin in a mouse L1210 leukemia model in vivo led to prolonged survival times of the animals.
18 Table 2 The combination index (CI) value at 50% effect on the cell culture (Fa 50 ) In the three cell lines evaluated in our studies, the use of 'classical' acute adult leukemia treatment with daunorubicin and cytosine arabinoside combined with dexrazoxane resulted in synergistic and not antagonistic results as measured by median effect analysis. An in vitro system is obviously not a complete reflection of in vivo disease. Therapeutic index cannot be determined, and most tumors are heterogeneous with heterogeneous growth patterns. In spite of these drawbacks, these results suggest that dexrazoxane should not be antagonistic with classical induction therapy in adult leukemia and might offer the advantage of cardioprotection. An additional potential advantage is that overexpression of the drug resistance transport proteins or downregulation of topoisomerase II did not result in resistance to the cytotoxic effects of dexrazoxane. 32 Further interest in this agent is the finding that dexrazoxane delays the expression of the multidrug resistance transporter (MDR-1) protein in a leukemic cell line exposed to doxorubicin. 20 These current findings suggest a potential role of this agent in adult acute leukemia as the dose intensity of anthracycline treatment is intensified. Further studies are warranted.
